SEARCH:   Advanced

Blood, 15 April 2006, Vol. 107, No. 8, pp. 3027-3033. Prepublished online as a Blood First Edition Paper on December 22, 2005; DOI 10.1182/blood-2005-10-4114. This Article Full Text (PDF) All Versions of this Article: 2005-10-4114v1 107/8/3027    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Liu, Y. Articles by Deisseroth, A. Search for Related Content PubMed PubMed Citation Articles by Liu, Y. Articles by Deisseroth, A. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted October 17, 2005 Accepted December 4, 2005 Tumor vascular targeting therapy with viral vectors Yanzheng Liu and Albert Deisseroth* Sidney Kimmel Cancer Center, San Diego, CA, USA * Corresponding author; email: adeisseroth{at}skcc.org. Tumor angiogenesis is crucial for the progression and metastasis of cancer. The vasculature of tumor tissue is different from normal vasculature. Therefore, tumor vascular targeting therapy could represent an effective therapeutic strategy with which to suppress both primary tumor growth and tumor metastasis. The use of viral vectors for tumor vascular targeting therapy is a promising strategy based on the unique properties of viral vectors. In order to circumvent the potential problems of anti-viral neutralizing antibodies, poor access to extravascular tumor tissue, and toxicities to normal tissue, viral vectors need to be modified to target the tumor endothelial cells. Viral vectors that could be used for tumor vascular targeting therapy include adenoviral vectors, adeno-associated viral vectors, retroviral vectors, lentiviral vectors, measles virus, and herpes simplex viral vectors. In this review, we will summarize the strategies available for targeting viral vectors for tumor vascular targeting therapy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Y. Jing, C. Tong, J. Zhang, T. Nakamura, I. Iankov, S. J. Russell, and J. R. Merchan Tumor and Vascular Targeting of a Novel Oncolytic Measles Virus Retargeted against the Urokinase Receptor Cancer Res., February 15, 2009; 69(4): 1459 - 1468. [Abstract] [Full Text] [PDF] C.-M. Hu and Z.-F. Chang Synthetic Lethality by Lentiviral Short Hairpin RNA Silencing of Thymidylate Kinase and Doxorubicin in Colon Cancer Cells Regardless of the p53 Status Cancer Res., April 15, 2008; 68(8): 2831 - 2840. [Abstract] [Full Text] [PDF] J. Qiao, H. Wang, T. Kottke, C. White, K. Twigger, R. M. Diaz, J. Thompson, P. Selby, J. de Bono, A. Melcher, et al. Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus Clin. Cancer Res., January 1, 2008; 14(1): 259 - 269. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020